- Provides scalable, decentralized, rapid response testing solutions to enable global expansion.
- Accelerates expansion into the chronic disease diagnostics market—a large, high-growth, global opportunity—by enabling additional assay development for long-term clinical indications.
- Creates synergies for sustained breakthrough innovation by combining Sugentech’s cutting edge technology with Response’s rapid response and commercialization capabilities, to support a pipeline of new tests and faster time-to-market globally.
Vancouver, Canada, [March 24, 2026] — Response Biomedical Corp. (Response), a leader in acute care diagnostics, today announced a strategic collaboration with Sugentech, Inc. (Sugentech, KOSDAQ: 253840) to support the advancement and commercialization of a next generation rapid response diagnostic platform for global markets.
Sugentech is a South Korea–based IVD company that develops next-generation in-vitro diagnostic products by combining biological technology and information technology, bringing diagnostic system expertise that complements Response’s experience in market development and commercialization of acute care near patient testing solutions. The collaboration reflects a shared focus on expanding access to high value diagnostic solutions in regions where decentralized or rapid response testing is increasingly essential to timely clinical decision-making.
“This collaboration is a natural fit for both organizations,” said Taso Tsonis, Interim CEO, Response Biomedical. “By bringing our strengths together, we can deliver scalable solutions that help clinicians make faster, more confident decisions in decentralized settings.”
“By combining the deep R&D expertise and extensive industry experience that both companies have built over many years in the point-of-care diagnostics field, we expect this collaboration to generate strong synergies and accelerate our expansion into global markets.” said Dr. Mi-Jin Sohn, CEO, Sugentech
By combining Sugentech’s advanced point-of-care technology with Response’s established commercial reach, we are uniquely positioned to expand our global footprint and accelerate the launch of innovative diagnostic solutions. Together, we enable patient care across the full continuum—from the pharmacy to the laboratory and every point in between. These complementary strengths create a compelling growth trajectory, unlocking new market opportunities and delivering meaningful healthcare impact and long-term value for our stakeholders.